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Several recent studies described that high-risk human papillomavirus (HPV) infection could have a
potential role in the development of malignancies other than cervical cancer, such as laryngeal carci-
noma, penile carcinoma, and anal carcinoma. However, the etiological role of HPV infection in the
pathogenesis of urinary tract has not been clariﬁed. Many epidemiological studies demonstrated that
HPV infections frequently occur in the external genitalia through sexual contact; however, it was re-
ported that HPV infection could also occur in the urinary tract, including the urethra and urinary bladder.
Some morphological changes of cells associated with HPV infection and mild atypical cells, suspected to
be intraneoplasia, were seen in HPV-positive samples obtained from the urinary tract. Some clinical
studies and meta-analysis have indicated that HPV infection is likely to have a certain etiological cor-
relation with the development of bladder carcinoma, although its prevalence may vary according to HPV
type, study population, region, histological type, detection methods, and other variables. According to the
results of previous studies, the prevalence of HPV greatly widely varies in cases of bladder carcinoma.
Further research by caseecontrol or large-scales studies is thus required to reach a more deﬁnite
conclusion.
© 2014, Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases.
Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Sexually transmitted human papillomavirus (HPV) infection has
been identiﬁed as a cause of cervical cancer, and it is now widely
recognized as responsible for more than 95% of cervical cancer
cases. Since the discovery of HPV 16 and 18 DNA in cervical cancer
tissue by zur Hausen's group [1], more than 100 types of HPV have
been isolated, and at least 15 types of high-risk HPV types have
been identiﬁed often in association with cervical cancer. HPV
infection in the cervix generally occurs in over 50% of young
women within a few years of sexual intercourse initiation, and
70e80% of women are likely to present the infection throughout
their lives [2]. Thus, cervical HPV infection is one of the most
common sexually transmitted infections (STIs) in women.
Conversely, many epidemiological studies described that the
prevalence of HPV among healthy men, who are considered only aIshikawa Prefectural Central
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d The Japanese Association for InfectiHPV reservoir, is as high as that among healthy women [3,4]. In
addition, several recent studies described that high-risk HPV
infection could have a potential role in the development of other
malignancies, such as laryngeal carcinoma, penile cancer, and anal
cancer [5e7]. Almost 10% of the cancer burdenworldwide has been
linked to HPV infection [8]. Thus, a quadrivalent HPV vaccine type 6,
11, 16, 18 (Gardasil®; Merck & Co., Inc, North Carolina, USA.) has
been developed and made available for men in over 70 countries
worldwide.
However, the etiological role of HPV infection in the patho-
genesis of urinary tract cancer has not been clariﬁed. In particular,
the association of HPV infection with the development of bladder
cancer continues to be controversial. To address this, we analyzed
some internationally published studies, and reviewed the possi-
bility of pathogenesis of HPV infection in urothelial epithelium.2. HPV infection in the urothelical epithelium
Although the prevalence of HPV varies on the basis of sampling,
processing methods, and/or samples specimens, the frequent
anatomic site for HPV infection in men is generally the externalous Diseases. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.
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Further, HPV infection in men is often detected in the glans, corona,
prepuce, shaft of the penis, and distal urethra [3,9]. Giuliano et al.
examined the presence of HPV-DNA in multiple genital sites of 463
healthy men and reported that HPV was most commonly detected
on the penile shaft (49.9%), followed by the glans (35.8%), scrotum
(34.2%), perianal area (20.0%), anal canal (17.6%), urethra (10.1%),
and semen (5.3%); the HPV detection rate was the poorest in urine
samples (0.8%) [9]. Furthermore, Nicolau et al. determined the
prevalence of HPV-DNA according to some anatomical sites in 50
male partners of HPV-infected women and found that HPV detec-
tion was 44% in the inner prepuce, 30% in the distal urethra, 24% in
the glans, 24% in the external prepuce of penile shaft, 12% in the
scrotum, and 8% in the anus [10].
However, many previous studies have failed to detect HPV
infection in the urinary tract, especially from urine samples. Giu-
liano et al. found a low HPV infection rate (0.8%) in urine samples
collected from 463 healthy men, with the adequacy rate of 51.5%
positive for the b-globin gene [9]. Lazcano-Ponce et al. investigated
HPV prevalence in samples obtained by rubbing the urethral-
coronal sulcus versus that of urine samples among 120 Mexican
healthy men, and described that HPV was detected in 42.7% of the
samples by rubbing versus 6.9% of the urine samples [11]. A sys-
tematic review also reported that the HPV detection rate from urine
samples was less than 7% [3], although higher HPV-positive rates
were observed in samples obtained by scraping the male external
genitalia, which suggests that urine may not be suitable for
detection of HPV.
However, the recent development of higher-sensitivity methods
using polymerase chain reaction (PCR) for the detection of a wide
spectrum HPV types and the improvement of sampling procedures
have contributed to a relative higher detection of HPV infection,
even in urine samples [4,12e14]. Our previous study demonstrated
that HPV infection was detected in 31%, 20%, and 24% of samples
obtained from the penis, urethra, and urine, respectively, by using
high-sensitivity ﬂow-through hybridization among patients with
urethritis [4]. Both urine and urethral samples were counted as
being from the same source (the urinary tract), and hence, the
prevalence was almost the same between the penis and the urinary
tract. Furthermore, Kawaguchi et al. demonstrated that application
of liquid-based cytology, which is widely used for uterine and
cervical cancer screening in women, is a promising method for
molecular analysis of HPV in the urinary tract [12]. The prevalence
of HPV in urine samples, detected using liquid-based cytology, was
21% in 136 patients with urethritis and 3.3% in 156 healthy men
(control), with adequacy detection rate of b-globin of more than
97% in both groups. In addition, another report described the
comparison of the HPV-positive rate between the oral cavity and
urine among patients who attended the STD clinic by using same
liquid-based cytology procedure, and found that HPV detection
rates were 18.8% and 22.1% in oral and urine samples, respectively
[13]. Moreover, the detection of HPV in urine samples suggests that
HPV could infect any site on the urinary tract, such as the urethra,
prostate, and urinary bladder. Since the studies including HPV
detection from urine samples using recent improvedmethods have
been limited, further studies are likely to be required.
3. The origin of HPV infection within the urinary tract
determined from urinary samples
Among the HPV-positive urine samples, it is important to
determine the origin of HPV infectionwithin the urinary tract, such
as the distal or proximal urethra, prostate, and urinary bladder. A
previous report conﬁrmed the localization of HPV-DNA in urothe-
lial cells, such as urethral squamous cells and bladder urothelialcells by in situ hybridization (ISH) analysis [12]. Further, some
studies have reported the occurrence of condyloma acuminata in
the urinary bladder [15,16]. A case with high-risk HPV-positive
bladder carcinoma that developed after the same high-risk type
HPV infection in the urethra has also been reported [17]. These
ﬁndings suggest that HPV ﬁrst infects the distal urethra by sexual
contact and ascends through the urethra into the urothelial
epithelium of the bladder, and thus, HPV infection can be detected
in the urothelial cells of the urinary bladder.
Furthermore, some reports demonstrated the presence of some
morphological changes of cells related to HPV infection and mild
atypical cells, suspected to be intraneoplasia, in HPV-positive
samples obtained from the urinary tract [12,18,19]. One study re-
ported that cytological signs of HPV infection and cytological aty-
pia, suspected to indicate urethral intraepithelial neoplasia, were
observed in 58% and 33%, of high-risk HPV-positive samples,
respectively [18]. A recent study to investigate cytological ﬁndings
in samples obtained by rubbing the urethral-coronal sulcus of 50
male sexual partners of women with HPV-related cervical disease
described that mild koilocytosis and dyskeratosis were observed in
48% and 48% of the cases, respectively [19]. Another study also
demonstrated that some morphological changes of cells related to
HPV infection were observed in 20.7% of the HPV-positive liquid-
based urine samples [12]. HPV infection in the urinary bladder may
cause cytological changes of the urothelial epitheliums, similar to
those in the HPV infected cervix. These ﬁndings suggest that HPV
infection may result in the development of tumors in the urinary
tract of men after persistent long-term infection.
4. HPV prevalence in bladder carcinoma
Kitamura et al. ﬁrst reported a HPV 16-positive case among 10
bladder tumors based on Southern blotting analysis in 1988 [20],
and suggested a possible etiological role in the development of
bladder carcinoma. Excluding the case reports and review articles,
56 subsequent studies have attempted to determine the associa-
tions between HPV infection and bladder carcinoma (Table 1)
[20e75]. The prevalence of HPV infection in bladder carcinoma
varies among reports, and ranges from 0% to 81.3%. Twenty-seven
reports suggested a potential correlation between HPV infection
and bladder carcinoma, whereas the other reports denied its etio-
logical role in bladder carcinogenesis, with the HPV prevalence rate
ranging from 0% to 10%. Therefore, the role of HPV in bladder car-
cinoma has still not been consensual.
Several explanations for this variability of HPV prevalence in
bladder carcinoma have been proposed, including sampling prob-
lems, contamination, differences in sensitivity of the detection
methods used, and differences among study populations and his-
tological tumor type. The mean sample size in the previous reports
was 60 (ranging from 10 to 187), and large population studies,
including more than 100 subjects, are limited. Further, there have
also been limited studies, including usage of the high-sensitivity
PCR method, which can detect a wide spectrum of HPV types.
Thus, it is important to investigate a sufﬁcient number of cases by
using a standardized microbiological technique to reach more
deﬁnite conclusions.
5. Comparison of HPV prevalence between bladder carcinoma
and non-carcinomatous mucosa
Nineteen previous studies compared HPV-positive rate between
bladder carcinoma and non-carcinomatous lesions, such as non-
speciﬁc cystitis and normal mucosa (Table 2), and the prevalence
of HPV varied on the basis of sampling, processing method, or
geographic location of study population. Thirteen (68%) studies
Table 1
Details of the previous studies on HPV prevalence of bladder carcinoma.
Author
[reference]
Year Samples Pathology N Methods Analyzed HPV-types HPV
detection
(%)
Detected HPV types (number)
Kitamura [20] 1988 Frozen UC/AD 10 PCR þ dot blot 1,2,6,11,16,18 1 (10%) Type 16 (1)
Bryant [21] 1991 Fixed UC/AD 100 ISH 6/11, 16/18 12 (12%) Type 16/18 (12)
Kerleys [22] 1991 Fixed UC/SCC/AD 27 PCR þ ISH 6,11,16,18.31,33,35 1 (3.7%) Type 11 (1)
Knowles [23] 1992 Frozen UC/SCC/AD 108 PCR þ SBH 1/2,5/6 þ 5,8,11,16,18,33 0 (0%) None
Chetsanga [24] 1992 Frozen UC 44 PCR þ dot blot Not detailed 1 (2.3%) Type 16 (1)
Shibutani [25] 1992 Frozen UC 20 SBH 6/11, 16/18, 31/33 4 (20%) Type 6/11 (2), type 16/18 (1),
type 31/33 (1)
Anwar [26] 1992 Fixed UC/SCC 48 PCR þ dot blot 6,11,16,18,33 39 (81%) Type 18 (18), type 33 (14),
type 16 (13)
Yu ST [27] 1993 Frozen UC 53 PCR 16, 18 30 (57%) Type 16 (28), type 18 (2)
Wilczynsky [28] 1993 Frozen SCC 22 PCR þ SBH 6,11,16,18 1 (4.5%) type 6 (1)
Sinclair [29] 1993 Frozen UC 14 PCR GP5þ/GP6þ, MYO9/11 (not detailed) 0 (0%) None
Saltzstein [30] 1993 Frozen/ﬁxed UC 33 PCR þ SBH 6,11,16,18,31,33 0 (0%) None
Furihata [31] 1993 Fixed UC 90 ISH 16, 18, 33 28 (31%) None
Mincione [32] 1994 Fixed UC 18 ISH 6/11, 16/18, 31/33/51 1 (5.6%) Type 31/33/51 (1)
Chang [33] 1994 Fixed UC 108 ISH þ PCR 6,11,16,18,31,33,35,39,40,45,51,59 0 (0%) None
Agliano [34] 1994 Fixed UC 46 PCR þ dot blot 16,18 23 (50%) Type 16 (11), type 18 (7),
type 16/18 (7)
Maloney [35] 1994 Fixed UC/SCC 42 PCR 6/11/13/16/18/31/32/33/35/45/51 1 (4.4%) Type 18 (1)
Noel [36] 1994 Fixed UC 75 PCR 6b,11,16,18,33 2 (2.7%) Type 16 (2)
Kamel [37] 1995 Fixed UC/SCC 47 ISH 6,11,16,18,31,33 27 (57%) Type 31 (19), type 18 (16),
type 33 (13)
Type 16 (10), type 11 (10),
type 6 (13)
Sano [38] 1995 Fixed BT 93 PCR þ ISH Multiple type þ ISH16, 18 prove 0 (0%) None
Kim [39] 1995 Fixed UC 23 PCR þ dot blot 6/11/16/18/31/33 8 (35%) Type 16 (4), type 18 (8)
Smetana [40] 1995 Frozen UC 110 ISH þ IHC þ PCR Wide-PCR, 6/11,16/18,31/33/35 59 (54%) Not detailed
LaRue [41] 1995 Frozen UC 71 PCR/SBH Wide-PCR; 6,11.16,18,33 28 (39%) Type 16 (27), type 6/11 (1)
Lopez-Beltran [42] 1995 Fixed UC 76 PCR/ISH 6,11,16,18 (þ31/33/35) 7 (9.2%) Type 16 (7)
Gopalkrishna [43] 1995 Fixed UC 10 PCR/ISH 16 1 (10%) Type 16 (1)
Tenti [44] 1996 Fixed UC 79 PCR þ SBH 6/11, 16,18, 33 26 (33%) Type 16 (21), type 18 (8)
Lopez-Beltran [45] 1996 Fixed UC 76 PCR 6, 11, 16, 18 7 (9.2%) Type 16 (7), type 6 (1)
Mvula [46] 1996 Fixed UC/SCC 36 PCR 16,18, wide PCR(6/11/31/33/42/52/58) 1 (2.8%) Type 16 (1)
Lopez-Beltran [47] 1996 Fixed UC 76 IHC þ ISH 6/11, 16/18, 31/33/35 25 (33%) Type 16/18 (12), UK (13)
Boucher [48] 1996 Fixed UC/SCC 55 SBH 6/11, 16 0 (0%) None
Lu [49] 1997 Fixed UC/SCC/AD 31 ISH 16,18 0 (0%) None
Cooper [50] 1997 Fixed SCC 25 PCR þ ISH 6,11,16,18,31,33 0 (0%) None
Chan [51] 1997 Fixed UC 20 PCR þ SBH 6,11,16,18,31,33 6 (30%) type18 (6)
Aynaud [52] 1998 Frozen UC 57 PCR þ dot blot 6,11,16,18,31,33,35,39,42 0 (0%) None
Gazzaniga [53] 1998 Frozen UC 35 PCR þ dot blot 16, 18 11 (31%) Type 16 (6), type 18 (5)
De Gaetani [54] 1999 Fixed UC 43 ISH 6/11,16/18, 31/33/35 17 (40%) Type 6/11 (3), type 16/18 (6),
type 31/33/35 (10)
Simoneau [55] 1999 Frozen UC 187 PCR þ dot blot 6,11,16,18, 33 16 (8.5%) Type 16 (6), type 6 (3), type 11 (3)
Tekin [56] 1999 Frozen UC 42 PCR 16,18 2 (4.8%) Type 16 (2)
Khaled [57] 2001 Fixed UC/SCC/AD 50 ISH 16/18 23 (46%) Type 16/18 (23)
Sur [58] 2001 Fixed UC 91 PCR þ ISH GP5þ/GP6þ, prove 6,11,16,18,31,33 1 (1.5%) None
Westenend [59] 2001 Fixed SCC 16 ISH 6/11,16/18,31/33/51 0 (0%) None
Fioriti [60] 2003 Frozen UC 32 PCR GP5þ/GP6þ (Not detailed) 1 (3%) Type 6 (1)
Khaled [61] 2003 Fixed UC/SCC 99 PCR 6,11,16,18,33 48 (49%) Type 16 (36), type 18 (14),
type 6 (3), type 11 (3)
Barghi [62] 2005 Fixed UC 59 PCR 6,11,16,18,31,33,35 21 (36%) Type 18 (17), type 6 (4),
type 33 (3)
Youshya [63] 2005 Fixed UC 78 PCR þ IHC GP5þ/GP6þ (Not detailed) 0 (0%) None
Helal [64] 2006 Fixed UC/SCC 114 ISH 6/11,16/18,31/33 1 (0.9%) Type 16 (1)
Moonen [65] 2007 Wash UC 99 PCR GP5þ/GP6þ(6,11,18,31,33,39,40,52) 15 (15%) Type 18 (3), type 16 (2),
type 6 (1), type 11 (1)
Type 31 (1), type 40 (1),
type 52 (1), UK type (1)
Badawi [66] 2008 Frozen UC/SCC 20 PCR 16,18,52 9 (45%) Type16 (9), type18 (2)
Ben Selma [67] 2010 Fixed UC/SCC/AD 125 PCR 6,11,16,18,30,31,33,35,45,51,52,58 0 (0%) None
Yavuzer [68] 2011 Fixed UC 70 PCR 6,11,16,18,31,33,35,39,42,43,44,45,51,52,56 0 (0%) None
58,59,66,68
Shigehara [69] 2011 Frozen/ﬁxed UC/SCC/AD 117 PCR þ ISH þ IHC 6,11,16,18,31,33,35,39,42,43,44,45, 18 (15%) Type16 (6), type18 (4), type33 (3),
type 31 (1)
51,52,53,56,58,59,66,68,CP8304 Type52 (1), type56 (1), type58(1),
UK type (1)
Cai [70] 2011 Frozen UC 78 PCR 6,11,16,18,26,31,33,35,39,40,43,44,45,51,52 27 (35%) Type 16 (4), type 18 (6),
type 31 (3), type 45 (5)53,54,56,58,59,66,68,69,70,71,73,74,82
Polesel [71] 2012 frozen UC 114 PCR 16,18,26,31,33,35,39,45,51,52,53,56,58,59 7 (6.1%) Type 56 (2), type 31 (1),
type 35 (1), type 45 (1)
66,68,70,73,82 type 58 (1), type 70 (1)
(continued on next page)
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Table 1 (continued )
Author
[reference]
Year Samples Pathology N Methods Analyzed HPV-types HPV
detection
(%)
Detected HPV types (number)
Barghi [72] 2012 Frozen UC 82 PCR 16/18 24 (29%) Type 18 (9), type 16 (3),
UK type (12)
Steinestel [73] 2013 Fixed CIS 60 PCR 6,11,16,18,31,33,35,39,45,51,52,53,56,58,59 0 (0%) None
Berrada [74] 2013 Fixed UC/SCC 43 PCR GP5/6, MY09/MY11 (Not detailed) 22 (52%) Type 18 (21), type 31 (1)
Kim [75] 2014 Fixed UC 35 PCR 6,11,16,18,31 33,34.35,39,40,43,44,45,51,52 6 (17%) Type 18 (6)
56, 58, 59, 66, 68,34, 70
HPV, human papillomavirus; UC, urothelial carcinoma; AD, adenocarcinoma; SCC, squamous cell carcinoma; BT, bladder tumor; CIS, carcinoma in situ; PCR, polymerase chain
reaction; dot blot, dot blot hybridization; ISH, in situ hybridization; SBH, southern blot hybridization; UK, unknown.
K. Shigehara et al. / J Infect Chemother 20 (2014) 741e747744demonstrated that the HPV prevalence (12e81%) in bladder carci-
nomawas signiﬁcantly higher compared with that (0e33%) in non-
carcinomatous bladder mucosa, and have supported the etiological
role of HPV in the development of bladder carcinoma. Many of
recent caseecontrol studies are especially likely to suggest a
possible correlation with HPV carcinogenesis by using the high-
sensitivity PCR method. One previous caseecontrol study re-
ported that HPV-DNA was detected in 18 of 117 (15%) bladder car-
cinomas and this ﬁnding was supported by the presence of HPV-
DNA signals by ISH analysis in HPV-positive samples [69]. Alter-
natively, Cai et al. described that high-risk HPV-DNA in bladder
carcinoma was detected in 27 of 78 (34.6%) samples, and was also
detected in 36 of 78 (46.1%) urine samples obtained from theTable 2
Case-control studies on HPV prevalence in bladder carcinoma.
Author [reference] Year Samples Pathology N HPV detection
Control
Bryant [21] 1991 Fixed UC
BPH
100
8
12 (12%)
0 (0%)
Kerleys [22] 1991 Fixed UC/SCC/AD
Normal
27
5
1 (3.7%)
0 (0%)
Knowles [23] 1992 Frozen UC/SCC/AD
cystitis
108
3
0 (0%)
0 (0%)
Anwar [26] 1992 Fixed UC/SCC
Normal
48
21
39 (81%)
7 (33%)
Yu ST [27] 1993 Frozen UC
Normal
53
8
30 (57%)
0 (0%)
Agliano [34] 1994 Fixed UC
Normal
46
10
23 (50%)
0 (%)
Noel [36] 1994 Fixed UC
normal
75
15
2 (2.7%)
0 (0%)
Smetana [40] 1995 Frozen UC
Normal
110
41
59 (54%)
2 (4.9%)
LaRue [41] 1995 Frozen UC
Normal
71
8
28 (39%)
0 (0%)
Gazzaniga [53] 1998 Frozen UC
Normal
35
10
11 (31%)
0 (0%)
Tekin [56] 1999 Frozen UC
Normal
42
10
2 (4.8%)
0 (0%)
Fioriti [60] 2003 Frozen UC
Normal
32
20
1 (3%)
0 (0%)
Barghi [62] 2005 Fixed UC
Normal
59 21 (35.6%)
1 (5.0%)20
Badawi [66] 2008 Frozen UC/SCC
Normal
20
20
9 (45%)
0 (0%)
Shigehara [69] 2011 Frozen/ﬁxed UC/SCC/AD
Normal
117
10
18 (15%)
0 (0%)
Cai [70] 2011 Frozen UC
Normal
78
59
27 (34.6%)
6 (10.1%)
Berrada [74] 2013 Frozen UC/AD
Normal
43
5
22 (52.4%)
5 (100%)
Kim [75] 2014 Fixed UC
Metaplasia
35
12
6 (17.1%)
1 (8.3%)
HPV, human papillomavirus; UC, urothelial carcinoma; AD, adenocarcinoma; SCC,
squamous cell carcinoma.patients with bladder carcinoma [70]. Conversely, HPV was detec-
ted in six of 59 (10.1%) specimens from patients without cancer, and
this study highlights the correlation between urothelial bladder
carcinoma and high-risk type HPV infection, suggesting the po-
tential pathogenetic role of high-risk HPV types in urothelial
bladder carcinoma development [70].
A recent meta-analysis with 19 caseecontrol studies reported
an HPV prevalence of 16.88% (95% CI, 15.53%e18.31%) among the
bladder carcinoma cases, most of which were high-risk HPV types,
and suggested that infection with high-risk HPV types, especially
HPV type 16, may play a role in bladder carcinogenesis [76].
Another meta-analysis, including 21 studies, also found a signiﬁ-
cant effect between HPV and bladder carcinoma with an odds ratio
(OR) of 2.13 (95% CI, 1.54%e2.95%) [77].
HPV infection is likely to have a certain etiological correlation
with bladder carcinoma. However, in comparisonwith the fact that
HPV infection is responsible for more than 95% of cervical cancers,
the etiological role of HPV infection demonstrates a somewhat
minimal relationship in the development of bladder carcinoma.
6. HPV-type distribution detected from bladder carcinoma
Although HPV types 16 and 18 were analyzed in majority of the
previously conducted studies, a wide spectrum of HPV types were
recently determined by the PCR method. Most of the HPV types
detected from bladder carcinomawere high-risk ones. Type 16 was
consistently among the most common types; type 18 was also
detected with relative frequency. According to eight studies, type
18 was most frequently detected from bladder carcinoma
[26,35,51,62,65,72,74,75]. In some previous studies on HPV preva-
lence based on urine samples, type 18 was often detected along
with type 16 [11e13]. Therefore, HPV type 18 may infect the uro-
thelial epithelium with relatively more ease than other types.
7. Relationship between HPV infection and pathological type
or tumor grade of bladder carcinoma
Squamous cell carcinoma (SCC) is the most common histo-
pathological type of cancer in cervix, oropharynx, anus, and vagina,
which is thought to be strongly associated with HPV infection.
Conversely, 90% of bladder cancer cases are urothelial carcinoma
(UC), and the other 10% is SCC or adenocarcinoma. The HPV prev-
alence varied according to the histopathological types of bladder
carcinoma.
Westenend et al. found no HPV infection in 16 SCCs of the
bladder based on ISH analysis, and concluded that high-risk HPV
types were found only in four of 105 (3.8%) SCCs of the bladder, by
summarizing 17 previous reports [59]. Other previous studies also
failed to ﬁnd HPV infection in bladder SCC cases [28,59]. However,
HPV was detected from UC in almost all of the studies, which
supports the etiological role of HPV in the development of bladder
K. Shigehara et al. / J Infect Chemother 20 (2014) 741e747 745carcinoma, in contrast to cervical cancer, oropharyngeal cancer, and
anal cancer. SCC of the bladder is thought to be caused by prolonged
irritation by infection with certain microorganisms, use of
indwelling catheters, urinary stones, or schistosomiasis. Thus, HPV
infection may have little or no inﬂuence in the development of SCC
of the bladder.
With regard to pathological grades of bladder carcinoma, there
are some previous reports on the relationship between patholog-
ical grades and HPV detection. Tenti et al. has described that HPV
prevalence in 79 samples of bladder carcinomawas 32.9%, and HPV
infection was frequently found in low-grade (grade 1) tumors
compared with high-grade tumors [44]. Badawi et al. also
mentioned that HPV was detected in 44.4% of bladder carcinoma
cases, which tended to be frequent in low-grade tumors [66]. Our
previous study showed that HPV was positive in 38% of grade 1
(G1), 8.5% in grade 2 (G2), and 0% in grade 3 (G3) carcinomas, and
that HPV-DNA was more frequently detected in low-grade carci-
noma than in lesions of higher grades (G2 or G3) [69]. These
ﬁndings are consistent with the fact that HPV is frequently detected
in low-grade oropharyngeal carcinomas with good prognosis [78].
Conversely, another study investigated the prevalence of HPV
among the bladder wash samples in the patients with bladder
carcinoma, and found positive correlation between HPV-positive
rate and the pathological grade [65]. However, there is possibility
of contamination from other bladder or urethral sites, beside the
tumor tissue, when using bladder wash samples in this study. Thus,
further studies need to evaluate the relationship between HPV
prevalence and pathological grade.
Conversely, the pathological grade differed according to the
material settings in which the target samples were primary or
recurrent. Furthermore, the number of samples has been limited as
above, and further studies are required to reach a more deﬁnite
conclusion. The pathological grade generally has a potential effect
on the recuperation of the patients with bladder carcinoma. Thus, it
is an interesting issue on the effect of HPV infection in the prognosis
of patients with bladder carcinoma.
8. Findings on the surrogate genes expression in HPV-positive
bladder carcinoma
In the carcinogenic process of low-grade non-invasive bladder
cancer or high-grade invasive bladder cancer, two different bio-
logical pathways have been proposed. One pathway for low-grade
cancer is involved in chromosome 9 allelic loss and higher p16
expression, whereas another pathway for high-grade invasive
cancer is characterized by p53 mutation and lack of p16, Ras, or
ﬁbroblast growth factor receptor-3 (FGFR3) expression [79].
HPV-E6 protein and E7 are well known as oncogenic proteins.
HPV-E6 contributes to the loss of function of p53, one of the main
cancer-suppression genes, by ubiquitination of this gene and
enhancement of proteasome activity. In addition, E6 protein also
suppresses the transcription of p53 directly. As described above,
some previous studies described the relationships between HPV
infection and p53 expression in bladder carcinoma. Tenti et al.
indicated that HPV was more frequently detected in low-grade
tumors than in high-grade tumors in which mutations of p53
protein were commonly observed [44]. However, Moonen et al.
found no correlation between HPV infection and p53 over-
expression in high-grade tumors [65]. Kamel et al. also reported
that no correlations between HPV positivity and p53 protein
accumulation were observed in bladder carcinoma [37]. As other
events related to the p53 gene are commonly observed in bladder
carcinoma regardless of HPV detection, no deﬁnite conclusions on
the relationship between p53 expression and HPV infection can be
reached.Moreover, it is well known that another oncogenic protein, HPV-
E7, inactivates pRb, resulting in commencement of cell prolifera-
tion. P16-INK4a is the cancer suppression gene that suppresses
inactivation of the Rb protein, and the loss or mutation of p16
expression is often a critical event in the progression of many car-
cinomas, including bladder carcinoma [80]. However, high levels of
p16-INK4a expression are linked to HPV-E7 activity, and these
molecules are strongly expressed in high-grade cervical intra-
epithelial neoplasia and cervical cancer. Further, p16-INK4a is
known as a surrogate marker of HPV-E7 expression [81,82]. One
study reported that high levels of p16-INK4a expression were
observed in most HPV-positive bladder carcinomas, whereas p16-
INK4a was rarely expressed in HPV-negative carcinomas, and
signiﬁcantly higher scores for p16-INK4a were demonstrated in
HPV-positive tumors than in those negative for HPV by a scoring
system for distribution of immunohistochemistry signals [69]. This
ﬁnding suggests that the HPV-E7 protein was expressed in tumor
tissue of the HPV-positive cases, and that HPV infection may be
strongly associated with the development of bladder carcinoma.
However, two studies have denied the potential correlation be-
tween p16-INK4a expression and HPV infection in bladder carci-
noma [73,75]. Further studies are needed to clarify whether p16-
INK4a can also be a surrogate marker of HPV-E7 expression in
bladder carcinoma. Molecular studies are needed to clarify the
mechanism of HPV carcinogenesis and to elucidate the etiological
role of HPV infection in the development of bladder carcinoma.
9. The relationship between HPV-positive bladder carcinoma
and cervical neoplasm risk
The information on the relationship between HPV-positive
bladder carcinoma and cervical neoplasm risk has been extremely
limited. Barghi et al. investigated the relationship between cervical
dysplasia in women and the evidence of HPV infection in tissue
specimens obtained from the bladders of their spouses [72]. High-
risk HPV-DNAwas detected in 24 (29.3%) menwith bladder UC, and
four these 24 men with HPV-positive bladder tumor had cervical
dysplasia based on their Pap smear tests. However, no dysplasia
was found in those women whose husbands had HPV-negative
bladder tumors. Moreover, another study tried to determine the
critical factors and etiological role of HPV infection in the devel-
opment of female bladder tumor [83]. HPV-DNA was detected in
ﬁve (6.0%) of 84 eligible patients, and two HPV-positive cases had a
past history of cervical cancer. Interestingly, the same HPV type 16
was detected in the bladder tumor and cervical cancer in these two
cases.
Since HPV is transmitted by sexual contact, it is relevant to know
the risk of developing other HPV-induced cancers for the partners
of men or womenwith any HPV-positive cancers, including cervical
cancer or bladder carcinoma.
10. Conclusion
Many epidemiological studies have demonstrated that HPV
infection is frequently transmitted through sexual contact of
external genitalia, but it also affects the urinary tract, including the
urethra and urinary bladder. Furthermore, some reports demon-
strated the presence of some morphological changes of cells
related to HPV infection and mild atypical cells, suspected to be
intraneoplasia, in HPV-positive samples obtained from the urinary
tract. According to the results of some clinical studies or meta-
analysis, HPV infection is likely to have a certain etiological cor-
relation with the development of bladder carcinoma, although its
prevalence may vary by HPV type, study population, geographical
region, histological type, detection methods, and among other
K. Shigehara et al. / J Infect Chemother 20 (2014) 741e747746variables. However, since the HPV prevalence in bladder carci-
noma greatly varied in previous studies, further caseecontrol or
large-scales studies are required to reach a more deﬁnite
conclusion.Conﬂict of interest
None.
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